On July 17th, our partner Northeast ALS Consortium (NEALS) hosted a webinar, “NurOwn® Clinical Development Program,” which comprehensively explained past phase II results, the upcoming phase III study and Israeli Hospital Exemption Program. To give a full picture of the company’s past progress and future endeavors, the webinar was led by leadership at Brainstorm Cell Therapeutics, including President and CEO Chaim Lebovits and Chief Operating and Medical Officer Dr. Ralph Kern. Clinicians involved in the upcoming phase III trial also spoke, including Drs. Robert Brown, Anthony Windebank and Merit Cudkowicz. The Association has partnered with NEALS for over eight years and we are happy to collaborate to disseminate the most accurate, up-to-date information regarding ALS clinical trials.
Today, we sat down with Dr. Javier Jara, Research Assistant Professor at Northwestern University Feinberg School of Medicine, who just published groundbreaking work focused on brain inflammation caused by ALS. This work was published in the July issue of the Journal of Neuroinflammation. The ALS Association has proudly supported Dr. Jara since 2010 through both our Milton Safenowitz Postdoctoral Fellowship Program and a recent Investigator-Initiated Grant. We are happy to report on his achievements! Read more to learn about this exciting study and get to know Dr. Jara inside and outside the lab.
Today, we are pleased to be joined by a wonderful ALS advocate Rob Robertson from Belleville, Ill. Rob proudly served our country in the U.S. Army for many years that included time in an elite fighting force “The Screaming Eagles.” He and his family faced many challenges over his lifetime, but nothing could have prepared him for his ALS diagnosis. Read his story and how he is bravely fighting ALS as an advocate, by raising money for research and teaching his fellow veterans and others about this devastating disease. Thank you for sharing your story Rob!
Genentech, a member of the Roche group, has initiated a Phase I clinical study evaluating GDC-0134, an oral investigational medicine designed to block dual leucine zipper kinase (DLK), for the potential treatment of ALS. The trial is enrolling now in sites across the United States.
On May 14- 16 more than 600 advocates took part in a very successful National ALS Advocacy Conference here in Washington, DC. Of the 600 advocates, 130 were people living with ALS. On Sunday and Monday, national experts and officials briefed participants on The ALS Association priorities and other “hot topics” that they might encounter in their congressional meetings and Chapter Executives prepared their state delegations for Hill meetings.
The ALS Association is proud to announce three large research organizations — Project MinE USA, Answer ALS and the New York Genome Center (NYGC) — will be working collaboratively toward their mission for treatments and a cure for ALS. These global collaborative projects, supported by The ALS Association through ALS Ice Bucket Challenge donations, will share genome sequencing information and research expertise to move efforts forward more rapidly and efficiently. Read more to learn about how global partnerships advance ALS research.
The June issue of Scientific American on newsstands this month features, “Unlocking the Mystery of ALS,” which details the significant advances of ALS research over the years. The authors, Drs. Leonard Petrucelli at the Mayo Clinic in Jacksonville and Aaron Gitler at the Stanford University School of Medicine, thoughtfully explained the complicated science behind ALS, while weaving a story of its breakthroughs and the steps needed to get to the ultimate goal – an end to ALS. They covered genetic discovery, starting with SOD1 in 1993 through today, which has sky rocketed in recent years, largely in part due to the donations dedicated to ALS research through the ALS Ice Bucket Challenge. Exciting therapeutic advances were explained, like a gene silencing technique, called antisense oligonucleotide (ASO) therapy, a way to track disease progression and improve diagnosis, called biomarkers, and targeting the support cells of the brain, called glia, and more were all described in a clear way.